{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-011936","form_type":"8-K","ticker":"MIRA","cik":"0001904286","company_name":"MIRA PHARMACEUTICALS, INC.","filed_at":"2025-05-21T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.439126+00:00","generated_at":"2026-05-20T22:47:53.044038+00:00","sec_items":["1.01","5.02","3.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"MIRA Pharmaceuticals appoints Alan Weichselbaum as CFO; prior CFO Michelle Yanez resigns","bullets":["CFO Michelle Yanez resigned effective May 16, 2025; mutual separation not based on any disagreement.","Alan Weichselbaum appointed CFO effective May 15, 2025; also CFO of Telomir Pharma and CEO of The Wexus Group.","Employment agreement: $60,000 annual salary (part-time, 20 hrs/week), 75,000 stock options vesting over 12 months.","Weichselbaum brings over 30 years of corporate finance experience; previously at Philip Morris and Price Waterhouse."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-011936","json":"https://secwatch.observer/filing/0001641172-25-011936.json","markdown":"https://secwatch.observer/filing/0001641172-25-011936.md","text":"https://secwatch.observer/filing/0001641172-25-011936.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1904286/000164117225011936/0001641172-25-011936-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1904286/000164117225011936/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T22:47:53.044038+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5ac887e971","claim":"Alan Weichselbaum was appointed as Chief Financial Officer at MIRA PHARMACEUTICALS, INC..","evidence_excerpt":"Effective May 15, 2025, the Company appointed Alan Weichselbaum as the Chief Financial Officer of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1904286/000164117225011936/0001641172-25-011936-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"d3399d48e7","claim":"Michelle Yanez resigned as Chief Financial Officer at MIRA PHARMACEUTICALS, INC..","evidence_excerpt":"Effective May 16, 2025, Michelle Yanez and the Company mutually agreed to release Ms. Yanez from her position as Chief Financial Officer, Treasurer and Secretary of MIRA Pharmaceuticals, Inc. (the “Company”), effective on that date.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1904286/000164117225011936/0001641172-25-011936-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}